ArticleDrugs - real world outcomes2026
Safety and Effectiveness of Intravenous Belimumab in Patients with Systemic Lupus Erythematosus in South Korea: A Multicentre, Observational, Real-World Study.
Article in Drugs - real world outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn South Korea, belimumab is indicated for patients with systemic lupus erythematosus (SLE), including paediatric patients aged ≥ 5 years, and for adults with lupus nephritis, based on clinical trial evidence; however, real-world data in this population remain limited.
objectiveTo assess the real-world safety and effectiveness of intravenous (IV) belimumab administered in patients with SLE in South Korea.
methodsThis observational study (GSK Study 216984) enrolled patients with active SLE and patients with lupus nephritis across 18 South Korean institutions (July 2021-February 2023). Patients received on-label IV belimumab plus standard therapy (antimalarials, glucocorticoids and immunosuppressants). Data were collected for a minimum of 48 weeks as part of routine clinical practice (July 2021-March 2024). Safety was assessed by monitoring the incidence of adverse events (AEs), adverse drug reactions (ADRs), serious AEs (SAEs)/ADRs and AEs of special interest (including psychiatric events) and summarised descriptively. Changes in SELENA-SLEDAI scores, laboratory biomarkers and glucocorticoid dosage from baseline to week 24 or 48 were tested using the Wilcoxon signed-rank test.
resultsOf 126 enrolled patients, 105 were eligible for the ≥ 48-week safety evaluation (completed ≥ 24 weeks of belimumab treatment). Patients were mostly female (91.4%, n = 96/105), with mean (SD) SLE duration of 9.9 (8.1) years; 45.7% (n = 48/105) of patients had lupus nephritis. AEs and SAEs were experienced by 66.7% (n = 70/105) and 18.1% (n = 19/105) of patients; most events were mild or moderate in severity and unlikely to be related to belimumab. ADRs were reported for 3.8% (n = 4/105) of patients, and psychiatric events for 2.9% (n = 3/105). SELENA-SLEDAI and laboratory biomarkers significantly improved, and glucocorticoid dosage significantly reduced, between baseline and weeks 24 and 48.
conclusionsThis real-world study identified no new safety concerns and demonstrated effectiveness of belimumab, supporting its use in Korean patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.